[O25-2] O25-2: CNS and miscellaneous

[O25-2-1] CYP2C19 polymorphism affects the efficacy but not drowsiness in the low dose clobazam therapy

Sachiyo Hashi¹, Ikuko Yano², Mai Shibata³, Riki Matsumoto⁴, Akio Ikeda⁵, Atsushi Yonezawa⁶, Ryosuke Takahashi⁷, Kazuo Matsubara⁸ (1.Kyoto University Hospital, 2.Kobe University Hospital, 3.Kyoto University, 4.Kyoto University, 5.Kyoto University, 6.Kyoto University, 7.Kyoto University, 8.Kyoto University Hospital)

Keywords:CYP2C19, clobazam, N-desmethylclobazam, drowsiness, side effect